The University of Texas System

Dompé Farmaceutici S.p.a.

Golgi Neurosciences S.r.l.

Dompe S.p.a.

Axxam S.p.a.

Chiara Liberati

Silvia Bovolenta

Gianluca Bianchini

Philip Jones

Paolo Pevarello

Andrea Aramini

Russell Thomas

Laura Brandolini

Alessio Moriconi

William J Ray

Valentina Cusano

Domenica Torino

Ali Munaim Yousif

Mary Hamby

Yaima Luzardo Lightfoot

Andrea Beccari

Pierfausto Seneci

Francesco Piscitelli

Adolfo Prandi

Stefan Lohmer

Cristina Pesenti

Sandro Colagioia

Mara Zippoli

Michela Fani'

Simone Lorenzi

Andrea Rosario Beccari

Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Bicyclic CX3CR1 receptor agonists

The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula:  Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.

TRPM8 antagonists

The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders. 

The present invention relates to compounds represented by formula (I) and pharmaceutically acceptable salts thereof that are antagonists of the bradykinin B1 receptor. These compounds are useful for the treatment of disorders associated with the bradykinin B1 pathway, in particular pain-related disorders.

Bradykinin receptor antagonists and pharmaceutical compositions containing them

Compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (hereinafter referred to as TRPM8), having formula: Wherein Said compounds are useful in the prevention and treatment of pathologies depending on TRPM8 activity such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, inflammatory conditions and urological disorders.

TRPM8 receptor antagonists

Growing community of inventors

Milan, Italy

Chiara Liberati